Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
Pharvaris (PHVS) has announced a virtual R&D call scheduled for June 4, 2025, at 8:00 a.m. ET/14:00 CET, titled "Deucrictibant: Beyond HAE Type 1/2". The event will focus on exploring the potential applications of deucrictibant, their oral bradykinin B2 receptor antagonist, beyond hereditary angioedema (HAE) Type 1/2.
The presentation will cover bradykinin-mediated angioedema's pathophysiology and prevalence, current treatment landscape, unmet needs, and Pharvaris' biomarker approach for disease identification. Key speakers include medical experts from Amsterdam UMC and Pharvaris' leadership team, including their CEO, CMO, and Chief Early Development Officer.
Pharvaris (PHVS) ha annunciato una call virtuale di ricerca e sviluppo prevista per il 4 giugno 2025, alle 8:00 ET/14:00 CET, intitolata "Deucrictibant: Oltre l'HAE Tipo 1/2". L'evento si concentrerà sull'esplorazione delle potenziali applicazioni di deucrictibant, il loro antagonista orale del recettore della bradichinina B2, oltre l'angioedema ereditario (HAE) di Tipo 1/2.
La presentazione tratterà la fisiopatologia e la prevalenza dell'angioedema mediato dalla bradichinina, il panorama attuale dei trattamenti, le necessità non ancora soddisfatte e l'approccio di Pharvaris basato sui biomarcatori per l'identificazione della malattia. I relatori principali includono esperti medici dell'Amsterdam UMC e il team di leadership di Pharvaris, compresi il CEO, il CMO e il Chief Early Development Officer.
Pharvaris (PHVS) ha anunciado una llamada virtual de I+D programada para el 4 de junio de 2025 a las 8:00 a.m. ET/14:00 CET, titulada "Deucrictibant: Más allá del HAE Tipo 1/2". El evento se centrará en explorar las posibles aplicaciones de deucrictibant, su antagonista oral del receptor de bradicinina B2, más allá del angioedema hereditario (HAE) Tipo 1/2.
La presentación abordará la fisiopatología y prevalencia del angioedema mediado por bradicinina, el panorama actual de tratamientos, las necesidades no cubiertas y el enfoque de Pharvaris basado en biomarcadores para la identificación de la enfermedad. Los ponentes principales incluyen expertos médicos del Amsterdam UMC y el equipo directivo de Pharvaris, incluyendo su CEO, CMO y Chief Early Development Officer.
Pharvaris (PHVS)는 2025년 6월 4일 오전 8시 ET/오후 2시 CET에 "Deucrictibant: HAE 유형 1/2를 넘어서"라는 제목의 가상 연구개발 콜을 발표했습니다. 이번 행사는 구강용 브라디키닌 B2 수용체 길항제인 deucrictibant의 유전성 혈관부종(HAE) 유형 1/2 외 잠재적 적용 가능성을 탐구하는 데 중점을 둘 예정입니다.
발표에서는 브라디키닌 매개 혈관부종의 병태생리 및 유병률, 현재 치료 현황, 충족되지 않은 요구사항, 그리고 질병 식별을 위한 Pharvaris의 바이오마커 접근법에 대해 다룰 것입니다. 주요 연사로는 암스테르담 UMC의 의료 전문가들과 Pharvaris의 CEO, CMO, Chief Early Development Officer를 포함한 리더십 팀이 참여합니다.
Pharvaris (PHVS) a annoncé une conférence virtuelle de R&D prévue le 4 juin 2025 à 8h00 ET/14h00 CET, intitulée « Deucrictibant : Au-delà de l'HAE de type 1/2 ». L'événement portera sur l'exploration des applications potentielles de deucrictibant, leur antagoniste oral du récepteur de la bradykinine B2, au-delà de l'œdème de Quincke héréditaire (HAE) de type 1/2.
La présentation couvrira la physiopathologie et la prévalence de l'angio-œdème médié par la bradykinine, le paysage actuel des traitements, les besoins non satisfaits, ainsi que l'approche de Pharvaris basée sur les biomarqueurs pour l'identification de la maladie. Les principaux intervenants incluent des experts médicaux de l'Amsterdam UMC et l'équipe dirigeante de Pharvaris, comprenant leur CEO, CMO et Chief Early Development Officer.
Pharvaris (PHVS) hat einen virtuellen F&E-Call für den 4. Juni 2025 um 8:00 Uhr ET/14:00 Uhr CET angekündigt, mit dem Titel „Deucrictibant: Über HAE Typ 1/2 hinaus“. Die Veranstaltung wird sich auf die Erforschung der potenziellen Anwendungen von Deucrictibant, ihrem oralen Bradykinin-B2-Rezeptorantagonisten, über das hereditäre Angioödem (HAE) Typ 1/2 hinaus konzentrieren.
Die Präsentation behandelt die Pathophysiologie und Prävalenz des bradykininvermittelten Angioödems, die aktuelle Behandlungssituation, ungedeckte Bedürfnisse sowie den Biomarker-Ansatz von Pharvaris zur Krankheitsidentifikation. Zu den Hauptrednern gehören medizinische Experten vom Amsterdam UMC sowie das Führungsteam von Pharvaris, darunter CEO, CMO und Chief Early Development Officer.
- None.
- None.
Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema
ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that it will host a virtual R&D call, titled “Deucrictibant: Beyond HAE Type 1/2” on Wednesday, June 4, at 8:00 a.m. ET/14:00 CET.
The virtual event will explore the pathophysiology and prevalence of bradykinin-mediated angioedema, the current treatment paradigm and unmet needs of those living with bradykinin-mediated angioedema, the potential of deucrictibant to address those unmet needs, and Pharvaris’ biomarker approach to identification of those living with bradykinin-mediated angioedema and other diseases.
Presenters of the event are:
- Danny M. Cohn, M.D., Ph.D., Department of Vascular Medicine, Amsterdam UMC (an accredited center of ACARE)
- Anne Lesage, Ph.D., Chief Early Development Officer, Pharvaris
- Peng Lu, M.D., Ph.D., Chief Medical Officer, Pharvaris
- Berndt Modig, Chief Executive Officer, Pharvaris
To register for the live webcast, please visit https://ir.pharvaris.com/news-events/events-presentations in the News and Events section of the company’s website. Following the live webcast, an archived replay will be available for at least 30 days after the event.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.
Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications maggie.beller@pharvaris.com
FAQ
When is Pharvaris (PHVS) hosting its R&D call about deucrictibant?
What is the focus of Pharvaris' (PHVS) upcoming R&D presentation?
Who are the key speakers at Pharvaris' (PHVS) June 2025 R&D event?
How can investors access Pharvaris' (PHVS) R&D presentation?
